Kyorin Pharmaceutical Co., Ltd.

Gilead Connecticut, Inc.

Galapagos Nv

Alfasigma S.p.a.

Bei Li

Dimitrios Stefanidis

Anna Katrin Szardenings

Masahiro Nomura

Yasumichi Fukuda

Shigeki Seto

Rowchanak Pakdaman

Melissa Jean Casteel

Ayako Nakamura

Kyoko Okada

Kazuhiro Yumoto

Diana Sperger

Oana Cociorva

Yasushi Kohno

David Alonzo

Katrin Szardenings

Yasmuchi Fukuda

Pharmaceutical compositions comprising filgotinib maleate Form I, further comprising citric acid, and characterized by an XRPD pattern substantially the same as shown inand uses thereof are described herein.

Pharmaceutical compositions comprising a JAK inhibitor

Pharmaceutical compositions comprising filgotinib maleate Form I characterized by an XRPD pattern substantially the same as shown inand uses thereof are described herein.

Disclosed are pharmaceutical compositions comprising a compound having the formula: or a pharmaceutically acceptable salt thereof, or a hydrate of thereof, and at least one pharmaceutically acceptable polymer. The pharmaceutically acceptable salt of the compound of Formula I, or a hydrate thereof, can be a mesylate salt, including, for example, a mono-mesylate or a bis-mesylate salt, or a hydrate thereof. Also disclosed are methods of use for the pharmaceutical composition.

Formulation of syk inhibitors

Disclosed are pharmaceutical compositions comprising a compound having the formula: or a pharmaceutically acceptable salt thereof, or a hydrate of thereof, and at least one pharmaceutically acceptable polymer. The pharmaceutically acceptable salt of the compound of Formula I, or a hydrate thereof, can be a mesylate salt, including, for example, a mono-mesylate or a bis-mesylate salt, or a hydrate thereof. Also disclosed are methods of use for the pharmaceutical composition. 

Formulation of Syk inhibitors

Provided herein are spirocyclic aminoquinolones of formula I and compositions containing the compounds. The compounds and compositions provided herein are useful in the prevention, amelioration or treatment of GSK-3 inhibitors mediated diseases.

Spirocyclic aminoquinolones as GSK-3 inhibitors

Provided herein are spirocyclic aminoquinolones of formula I and compositions containing the compounds. The compounds and compositions provided herein are useful in the prevention, amelioration or treatment of GSK-3 inhibitors mediated diseases. In Formula (I): Xis O or NR; A is bond or substituted or unsubstituted C-Calkylene, wherein the substituents when present are selected from one to four Qgroups; where Qis alkyl or haloalkyl; p is 0 or 1; and q is an integer of 0 to 2. 

Provided herein are aminoquinolones and pharmaceutically acceptable derivatives thereof. In certain embodiments, provided herein are compounds, compositions and methods for treating, preventing or ameliorating GSK-3 mediated diseases. 

Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors

Provided herein are aminoquinolones and pharmaceutically acceptable derivatives thereof. In certain embodiments, provided herein are compounds, compositions and methods for treating, preventing or ameliorating GSK-3 mediated diseases.

Growing community of inventors

Foster City, CA, United States of America

Bei Li